A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Recruiting

Phase 3

KarXTA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Sponsor:

Bristol-Myers Squibb

Code:

NCT06951698

Conditions

Bipolar-I Disorder With Mania or Mania With Mixed Features

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

KarXT

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-05. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-07-27.